Biomarkers for concussion

Concussions in Athletics: From Brain to Behavior

Volumn , Issue , 2014, Pages 235-248

  Papa, Linda ^a,b,c,d  

^a ORLANDO REGIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biochemical markers; Biomarkers; Blood; Cerebrospinal fluid; Concussion; Detection; Diagnosis; GFAP; Head injury; MBP; Mild TBI; Monitoring; Neurofilament proteins; NSE; Pathophysiology; Prognosis; Proteomics; Risk stratification; S100 beta ; SBDP145; SBDP150; Serum; Tau; UCH L1

Indexed keywords

EID: 84930008976     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0295-8     Document Type: Chapter

References (113)

1. Kesler EA. APECT, MR and quantitative MR imaging: correlates with neuropsycholgical. Brain Inj. 2000;14:851-7.
2. Jagoda AS, Bazarian JJ, Bruns Jr JJ, Cantrill SV, Gean AD, Howard PK, et al. Clinical policy: neuroimaging and decisionmaking in adult mild traumatic brain injury in the acute setting. Ann Emerg Med. 2008;52(6):714-48.
3. Benson RR, Gattu R, Sewick B, Kou Z, Zakariah N, Cavanaugh JM, et al. Detection of hemorrhagic and axonal pathology in mild traumatic brain injury using advanced MRI: implications for neurorehabilitation. NeuroRehabilitation. 2013;31(3):261-79.
4. Govind V, Gold S, Kaliannan K, Saigal G, Falcone S, Arheart KL, et al. Whole-brain proton MR spectroscopic imaging of mild-to-moderate traumatic brain injury and correlation with neuropsychological deficits. J Neurotrauma. 2010;27(3):483-96.
5. Millis SR, Rosenthal M, Novack TA, Sherer M, Nick TG, Kreutzer JS, et al. Long-term neuropsychological outcome after traumatic brain injury. J Head Trauma Rehabil. 2001;16(4):343-55.
6. Alves W, Macciocchi S, Barth JT. Postconcussive symptoms after uncomplicated mild head injury. J Head Trauma Rehabil. 1993;8(3):48-59.
7. Rimel RW, Giordani B, Barth JT, Boll TJ, Jane JA. Disability caused by minor head injury. Neurosurgery. 1981;9(3):221-8.
8. Alexander MP. Mild traumatic brain injury: pathophysiology, natural history, and clinical management. Neurology. 1995;45(7):1253-60.
9. Barth JT, Macciocchi SN, Giordani B, Rimel R, Jane JA, Boll TJ. Neuropsychological sequelae of minor head injury. Neurosurgery. 1983;13(5):529-33.
10. Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med. 2011;30(1):179-88, 11.
11. Gavett BE, Cantu RC, Shenton M, Lin AP, Nowinski CJ, McKee AC, et al. Clinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions. Curr Opin Neurol. 2012;24(6):525-31.
12. Graham DI, Adams JH, Nicoll JA, Maxwell WL, Gennarelli TA. The nature, distribution and causes of traumatic brain injury. Brain Pathol. 1995;5(4):397-406.
13. Graham DI, Horsburgh K, Nicoll JA, Teasdale GM. Apolipoprotein E and the response of the brain to injury. Acta Neurochir Suppl. 1999;73:89-92.
14. Povlishock JT, Katz DI. Update of neuropathology and neurological recovery after traumatic brain injury. J Head Trauma Rehabil. 2005;20(1):76-94.
15. Povlishock JT. Traumatically induced axonal injury: pathogenesis and pathobiological implications. Brain Pathol. 1992;2(1):1-12.
16. Kochanek PM, Berger RP, Bayr H, Wagner AK, Jenkins LW, Clark RS. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care. 2008;14(2):135-41.
17. Papa L. Exploring the role of biomarkers for the diagnosis and management of traumatic brain injury patients. In: Man TK, Flores RJ, editors. Proteomics—human diseases and protein functions. 1st ed. Rijeka, Croatia: InTech Open Access Publisher; 2012.
18. Papa L, Ramia MM, Kelly JM, Burks SS, Pawlowicz A, Berger RP. Systematic review of clinical research on biomarkers for pediatric traumatic brain injury. J Neurotrauma. 2013;30(5):324-38.
19. Papa L, Robinson G, Oli M, Pineda J, Demery J, Brophy G, et al. Use of biomarkers for diagnosis and management of traumatic brain injury patients. Expert Opin Med Diagn. 2008;2(8):937-45.
20. Xiong H, Liang WL, Wu XR. [Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation]. Sheng Li Ke Xue Jin Zhan. 2000;31(3):217-21.
21. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995;37(4):417-29.
22. Olsson B, Zetterberg H, Hampel H, Blennow K. Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol. 2011;95(4):520-34.
23. Missler U. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997;28:1956-60.
24. Ytreb0 LM, Nedredal GI, Korvald C, Holm Nielsen OJ, Ingebrigtsen T, et al. Renal elimination of protein S-100beta in pigs with acute encephalopathy. Scand J Clin Lab Invest. 2001;61:217-25.
25. Jonsson HJP, Hoglund P, Alling C, Blomquist S. The elimination of S-100b and renal function after cardiac surgery. J Cardiothorac Vasc Anesth. 2000;14:698-701.
26. Usui AKK, Abe T, Murase M, Tanaka M, Takeuchi E. S-100ao protein in blood and urine during open-heart surgery. Clin Chem. 1989;35:1942-4.
27. Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg. 1999;13(1):56-9.
28. Haimoto H, Hosoda S, Kato K. Differential distribution of immunoreactive S100-a and S100-b proteins in normal nonnervous human tissues. Lab Invest. 1987;57:489-98.
29. Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir (Wien). 1997;139(12):1161-4; discussion 1165.
30. Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma. 2000;17(8):641-7.
31. Korfias S, Stranjalis G, Boviatsis E, Psachoulia C, Jullien G, Gregson B, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med. 2007;33(2):255-60.
32. Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010;75(20):1786-93.
33. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM. Serum S100B concentrations are increased after closed head injury in children: a preliminary study. J Neurotrauma. 2002;19(11):1405-9.
34. Ingebrigtsen T, Romner B. Management of minor head injuries in hospitals in Norway. Acta Neurol Scand. 1997;95(1):51-5.
35. Waterloo K, Ingebrigtsen T, Romner B. Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury. Acta Neurochir (Wien). 1997;139(1):26-31; discussion 31-2.
36. Ingebrigtsen T, Romner B. Serial S-100 protein serum measurements related to early magnetic resonance imaging after minor head injury. Case report. J Neurosurg. 1996; 85(5):945-8.
37. Ingebrigtsen T, Waterloo K, Jacobsen EA, Langbakk B, Romner B. Traumatic brain damage in minor head injury: relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome. Neurosurgery. 1999;45(3):468-75; discussion 75-6.
38. Ingebrigtsen T, Romner B, Marup-Jensen S, Dons M, Lundqvist C, Bellner J, et al. The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj. 2000;14(12):1047-55.
39. Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B, et al. S100B serum level predicts computed tomography findings after minor head injury. J Trauma. 2007; 62(6):1452-6.
40. Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, et al. Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. 2006; 25(5):446-53.
41. Phillips JP, Jones HM, Hitchcock R, Adama N, Thompson RJ. Radioimmunoassay of serum creatine kinase BB as index of brain damage after head injury. Br Med J. 1980;281 (6243):777-9.
42. Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A. S-100 serum levels after minor and major head injury. J Trauma. 1998;45(4):765-7.
43. Piazza O, Storti MP, Cotena S, Stoppa F, Perrotta D, Esposito G, et al. S100B is not a reliable prognostic index in paediatric TBI. Pediatr Neurosurg. 2007;43(4):258-64.
44. Bechtel K, Frasure S, Marshall C, Dziura J, Simpson C. Relationship of serum S100B levels and intracranial injury in children with closed head trauma. Pediatrics. 2009;124(4): 704-798.
45. Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One. 2012;7(4):134-606.
46. Stalnacke BM, Tegner Y, Sojka P. Playing ice hockey and basketball increases serum levels of S-100B in elite players: a pilot study. Clin J Sport Med. 2003;13(5):292-302.
47. Stalnacke BM, Tegner Y, Sojka P. Playing soccer increases serum concentrations of the biochemical markers of brain damage S-100B and neuron-specific enolase in elite players: a pilot study. Brain Inj. 2004;18(9):899-909.
48. Rothoerl RD, Woertgen C. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;49(6):1490-1; author reply 2-3.
49. Romner B, Ingebrigtsen T. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;49(6):1490; author reply 2-3.
50. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergen G. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;49(5):1272-3.
51. Pelinka LE, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma. 2004;57(5):1006-12.
52. Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971;28(2):351-4.
53. Duchen LW. General pathology of neurons and neuroglia. In: Adams JA, Corsellis JAN, Duchen LW, editors. Greenfield’s neuropathology. London: Edward Arnold; 1984. p. 1-52.
54. Baydas G, Nedzvetskii VS, Tuzcu M, Yasar A, Kirichenko SV. Increase of glial fibrillary acidic protein and S-100B in hippocampus and cortex of diabetic rats: effects of vitamin E. Eur J Pharmacol. 2003;462(1-3):67-71.
55. Mouser PE, Head E, Ha KH, Rohn TT. Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer’s disease brain. Am J Pathol. 2006;168(3):936-46.
56. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 2000;31(11):2670-7.
57. Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999;45(1):138-41.
58. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma. 2004;21(11):1553-61.
59. van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta. 2002; 326(1-2):151-4.
60. Nylen K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgard B, et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci. 2006;240(1-2):85-91.
61. Mondello S, Papa L, Buki A, Bullock R, Czeiter E, Tortella F, et al. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care. 2011;15(3):R156.
62. Metting Z, Wilczak N, Rodiger LA, Schaaf JM, van der Naalt J. GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology. 2012;78(18):1428-33.
63. Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med. 2012;59(6):471-83.
64. Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, et al. Neurochemical aftermath of amateur boxing. Arch Neurol. 2006;63(9):1277-80.
65. Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F. Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage. Acta Neurochir (Wien). 1992;115(3-4):106-11.
66. Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature. 1978;276(5690):834-6.
67. Ergun R, Bostanci U, Akdemir G, Beskonakli E, Kaptanoglu E, Gursoy F, et al. Prognostic value of serum neuron-specific enolase levels after head injury. Neurol Res. 1998; 20(5):418-20.
68. Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol. 1995;43(3):267-70; discussion 70-1.
69. Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg. 1996;10(5):471-6.
70. Fridriksson T, Kini N, Walsh-Kelly C, Hennes H. Serum neuron-specific enolase as a predictor of intracranial lesions in children with head trauma: a pilot study. Acad Emerg Med. 2000;7(7):816-20.
71. Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg. 2005;103(1 Suppl):61-8.
72. Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma. 2007;24(12):1793-801.
73. Varma S, Janesko KL, Wisniewski SR, Bayir H, Adelson PD, Thomas NJ, et al. F2-isoprostane and neuron-specific enolase in cerebrospinal fluid after severe traumatic brain injury in infants and children. J Neurotrauma. 2003;20(8):781-6.
74. Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM. Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Acad Emerg Med. 2005;12(8):732-8.
75. Johnsson P, Blomquist S, Luhrs C, Malmkvist G, Alling C, Solem JO, et al. Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. Ann Thorac Surg. 2000;69(3):750-4.
76. Ramont L, Thoannes H, Volondat A, Chastang F, Millet MC, Maquart FX. Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin Chem Lab Med. 2005;43(11):1215-7.
77. Stalnacke BM, Ohlsson A, Tegner Y, Sojka P. Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game. Br J Sports Med. 2006;40(4):313-6.
78. Jackson P, Thompson RJ. The demonstration of new human brain-specific proteins by highresolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci. 1981;49(3):429-38.
79. Tongaonkar P, Chen L, Lambertson D, Ko B, Madura K. Evidence for an interaction between ubiquitin-conjugating enzymes and the 26S proteasome. Mol Cell Biol. 2000; 20(13):4691-8.
80. Gong B, Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect. 2007;20(6):365-70.
81. Siman R, Toraskar N, Dang A, McNeil E, McGarvey M, Plaum J, et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma. 2009;26(11):1867-77.
82. Papa L, Akinyi L, Liu MC, Pineda JA, Tepas III JJ, Oli MW, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med. 2010;38(1):138—44.
83. Brophy G, Mondello S, Papa L, Robicsek S, Gabrielli A, Tepas Iii J, et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (Uch-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma. 2011;28(6):861-70.
84. Berger RP, Hayes RL, Richichi R, Beers SR, Wang KK. Serum concentrations of ubiquitin C-terminal hydrolase-L1 and alphaII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. J Neurotrauma. 2012;29(1):162-7.
85. Papa L, Lewis LM, Silvestri S, Falk JL, Giordano P, Brophy GM, et al. Serum levels of ubiq-uitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg. 2012;72(5):1335-44.
86. Goodman SR, Zimmer WE, Clark MB, Zagon IS, Barker JE, Bloom ML. Brain spectrin: of mice and men. Brain Res Bull. 1995;36(6):593-606.
87. Riederer BM, Zagon IS, Goodman SR. Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells. J Cell Biol. 1986;102(6):2088-97.
88. Wang KK, Posmantur R, Nath R, McGinnis K, Whitton M, Talanian RV, et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem. 1998;273(35):22490-7.
89. McGinn MJ, Kelley BJ, Akinyi L, Oli MW, Liu MC, Hayes RL, et al. Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. J Neuropathol Exp Neurol. 2009;68(3):241-9.
90. Pike BR, Flint J, Dave JR, Lu XC, Wang KK, Tortella FC, et al. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 2004;24(1):98-106.
91. Ringger NC, O’Steen BE, Brabham JG, Silver X, Pineda J, Wang KK, et al. A novel marker for traumatic brain injury: CSF alphaII-spectrin breakdown product levels. J Neurotrauma. 2004;21(10):1443-56.
92. Cardali S, Maugeri R. Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci. 2006;50(2):25-31.
93. Pineda JA, Lewis SB, Valadka AB, Papa L, Hannay HJ, Heaton SC, et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 2007;24(2):354-66.
94. Papa L, D’Avella D, Aguennouz M, Angileri FF, de Divitiis O, Germano A, et al. Detection of alpha-II spectrin and breakdown products in humans after severe traumatic brain injury [abstract]. Acad Emerg Med. 2004;11(5):515-16.
95. Papa L, Lewis SB, Heaton S, Demery JA, Tepas JJ III, Wang KKW, et al. Predicting early outcome using alpha-II spectrin breakdown products in human CSF after severe traumatic brain injury [abstract]. Acad Emerg Med. 2006;13(5 Suppl 1):S39-40.
96. Papa L, Pineda J, Wang KKW, Lewis SB, Demery JA, Heaton S, et al. Levels of alpha-II spectrin breakdown products in human CSF and outcome after severe traumatic brain injury [abstract]. Acad Emerg Med. 2005;12(5 Suppl 1):139-40.
97. Farkas O, Polgar B, Szekeres-Bartho J, Doczi T, Povlishock JT, Buki A. Spectrin breakdown products in the cerebrospinal fluid in severe head injury—preliminary observations. Acta Neurochir (Wien). 2005;147(8):855-61.
98. Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, Tepas J, et al. AlphaII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. 2010;27(7):1203-13.
99. Brophy GM, Pineda JA, Papa L, Lewis SB, Valadka AB, Hannay HJ, et al. AlphaII-spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 2009;26(4):471-9.
100. Papa L, Wang KW, Brophy GM, Demery JA, Silvestri S, Giordano P, et al. Serum levels of spectrin breakdown product 150 (SBDP150) distinguish mild traumatic brain injury from trauma and uninjured controls and predict intracranial injuries on CT and neurosurgical intervention. J Neurotrauma. 2012;29(Abstract Suppl):93.
101. Kosik KS, Finch EA. MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum. J Neurosci. 1987;7(10):3142-53.
102. Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2002;2(2):131-50.
103. Shaw GJ, Jauch EC, Zemlan FP Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. Ann Emerg Med. 2002;39(3):254-7.
104. Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res. 2002;947(1):131-9.
105. Chatfield DA, Zemlan FP, Day DJ, Menon DK. Discordant temporal patterns of S100beta and cleaved tau protein elevation after head injury: a pilot study. Br J Neurosurg. 2002;16(5):471-6.
106. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem. 1989;37(2):209-15.
107. Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H, et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology. 2003;60(9):1457-61.
108. Marklund N, Blennow K, Zetterberg H, Ronne-Engstrom E, Enblad P, Hillered L. Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J Neurosurg. 2009;110(6):1227-37.
109. Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67(9):1600-4.
110. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001;66(3):510-6.
111. Julien JP, Mushynski WE. Neurofilaments in health and disease. Prog Nucleic Acid Res Mol Biol. 1998;61:1-23.
112. Buki A, Povlishock JT. All roads lead to disconnection?—Traumatic axonal injury revisited. Acta Neurochir (Wien). 2006;148(2):181-93; discussion 93-4.
113. Zurek J, Bartlova L, Fedora M. Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children. Brain Inj. 2012;25(2):221-6.